allografts have not improved pari passu with improvements in the short-term outcomes. 4 There are concerns related to interobserver variability regarding interpretation of biopsy findings. 5, 6 In addition, tubulitis in the kidney allograft, an essential criterion for histological diagnosis of Banff acute T cell-mediated rejection, is often missed in the absence of immunostaining of the allograft biopsy for T cell CD3 protein. 7 An additional issue is that the current Banff scoring system is semiquantitative. 2, 3 Thus, development of precise quantitative measures to monitor allograft status might be of value.
Transplantation is a unique situation from a genetic perspective.
Two RNA sequencing has enabled genome-wide transcriptome profiling at an unprecedented level of precision, [8] [9] [10] [11] and is being increasingly applied to clinical investigation, including kidney allograft pathologies. [12] [13] [14] Recent advances in computational methods have enabled the extraction of additional genomic information from the RNA sequence data. [15] [16] [17] [18] [19] Variant calling of single nucleotide polymorphisms (SNPs), hitherto a domain of DNA sequencing, is now possible using mRNA sequencing data and novel bioinformatics tools. [20] [21] [22] In this approach, the ratio of heterozygous variants to nonreference homozygous variants (Het/Hom ratio) is generally used as a quality control measure in DNA sequencing, 23, 24 because it offers accurate resolution of genome admixture, often due to experimental errors, such as sample cross-contamination. Because the kidney allograft infiltrated by the recipient's cells is a unique situation of admixture of 2 genomes, we reasoned that variant calling on RNA sequencing of kidney allograft biopsy specimens and therefrom derived Het/Hom ratios could function as a quantitative measure for the invasion of the transplant organ by the recipient's cells. We further reasoned that a method used in cancer studies to estimate purity scores for the degree of stromal and immune cell invasion of tumor tissue (called ESTIMATE) may also be of use to gauge graft infiltration, because this method is based on cell-type-specific gene expression levels. 25 In this first-in-its-kind study, we report that kidney allograft biopsies manifesting cellular invasion have higher Het/Hom ratios and ESTIMATE scores compared to pristine biopsies from patients without manifest allograft rejection. We observe significant relationships between Banff biopsy classification and Het/Hom ratios and between Banff biopsy classification and the ESTIMATE scores. Moreover, we find a robust correlation between the Het/ Hom ratios and ESTIMATE scores. This is of interest because the 2 methods are based on different readouts of the mRNA sequencing data: The Het/Hom ratio is derived from genetic variance while the ESTIMATE score is based on cell-type-specific gene expression. In order to establish robust Het/Hom ratios of single genomes using RNA sequencing data, we leveraged a publicly available database of mRNA and small RNA sequencing data from 462 F I G U R E 1 Workflow of the study. Forty allograft biopsy specimens obtained from 40 unique kidney allograft recipients were RNA sequenced. For each sample: (i) Biopsy infiltration score was derived as the sum of Banff acute scores, reported by the transport pathologist; (ii) A purity score was computed using the aligned RNA sequencing reads as input in ESTIMATE software; and (iii) Het/Hom ratio was computed after variant calling was done from the RNA sequencing data. Throughout the article, the ratio of heterozygous to nonreference genome homozygous variants on all autosomes, for each sample, is called the Het/Hom ratio, and the ESTIMATE score and 1-Purity score are used interchangeably. ESTIMATE, estimation of stromal and immune cells in malignant tumors using expression data; Het/ Hom, heterozygosity to nonreference genome homozygosity ratio; SNPs, single nucleotide polymorphism [Color figure can be viewed at wileyonlinelibrary.com] 
| MATERIAL S AND ME THODS

| Study groups and allograft biopsies
We studied 40 adult recipients of human kidney allografts, a subset of kidney allograft recipients transplanted and followed at our center, the New York Presbyterian-Weill Cornell Medical College.
All recipients provided written informed consent to participate in the study, and our Institutional Review Board approved the study.
The clinical and research activities that we report here are consistent with the principles of the "Declaration of Istanbul on Organ
Trafficking and Transplant Tourism." The overall workflow used in this investigation is shown in Figure 1 .
Each study participant underwent ultrasound-guided percuta- 
| RNA sequencing of allograft biopsies
At the time of allograft biopsy, a portion of the biopsy tissue was immediately submerged in RNAlater ® RNA stabilization solution (Life Technologies, Grand Island, NY) and stored at −80°C. We isolated total RNA from the stored biopsy tissues using miRNeasy mini kit (Qiagen, Inc., Valencia, CA). The quantity and purity of the RNA were measured using NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE) and the RNA integrity number using Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA). For mRNA sequencing we used 400 ng of total RNA obtained from each biopsy sample. We used the TruSeq ™ sample preparation F I G U R E 2 Histopathological characteristics of the 40 kidney allograft biopsies. The histopathological characteristics of the 40 kidney allograft biopsies obtained from 40 kidney allograft recipients ("Sample #" 1 through 40) are shown. Biopsy tissue sections were stained with hematoxylin and eosin, periodic acid-Schiff, and Masson trichrome for light microscopic evaluation. Staining for polyoma virus was done using affinity-purified and agarose-conjugated IgG 2a mouse monoclonal antibody (Calbiochem, San Diego, CA) that recognizes a 94-kDa SV40 large T antigen. Indirect immunofluorescence for complement factor 4 degradation (C4d) product was done on cryosections using a monoclonal anti-C4d antibody (Quidel, Santa Clara, CA). These biopsies were categorized using the Banff 2017 update of the Banff '97 classification. The Banff diagnostic categories include acute T cell-mediated rejection ("Acute TCMR," Sample # 1 through 11), active antibody-mediated rejection ("Active ABMR," 12 through 18), chronic active antibody-mediated rejection ("Chronic Active ABMR," 19 through 29), interstitial fibrosis and tubular atrophy ("IFTA," 30 through 35), and normal (36 through 40). The median number of glomeruli per biopsy sample was 16 (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Colors represent Banff scores 0 to 3. Banff acute scores include the "t" (tubulitis) score, "i" (interstitial inflammation) score, "g" (glomerulitis) score, "ptc" (peritubular capillary inflammation) score, and "v" (vascular inflammation). Banff chronic scores include the "ci" (interstitial fibrosis) score, "ct" (tubular atrophy) score, "cg" (chronic glomerulopathy) score, "cv" (chronic vascular lesions) score, and "ah" (arteriolar hyaline thickening score). Also shown in the figure is the staining for complement factor 4d (C4d) in the peritubular capillaries. Immunohistochemical staining for CD3+ T cells, CD68+ monocytes/macrophages, and CD20+ B cells was performed on all kidney allograft biopsies showing acute TCMR, active ABMR or chronic active ABMR using CD3, CD68, and CD20 antibodies (Leica Biosystems, Buffalo Grove, IL), respectively, on paraffin-embedded tissue sections on a Leica Bond system (Buffalo Grove, IL) using the modified protocol F provided by the manufacturer. The section was pretreated using heat-mediated antigen retrieval with Tris-EDTA buffer (pH = 9, epitope retrieval solution 2) for 20 min and incubated with the antibodies for 15 min at room temperature. CD3, CD20, and CD68 were detected using a horseradish peroxidase-conjugated compact polymer system and 3,3'-Diaminobenzidine as the chromogen. Each section was counterstained with hematoxylin and mounted with Leica Micromount. For each biopsy tissue sample, the total number of CD3, CD20, or CD68 positive cells in 5 high-power fields (40×) in the nonsclerotic areas of the kidney allograft was counted and expressed as total number of cells per high-power field. In the table, the median (IQR) number of CD3+ T cells, CD68+ monocytes/macrophages and CD20+ B cells for each diagnostic category is shown. Kruskal-Wallis test was used for comparisons across the 3-biopsy diagnostic categories and the Dunn's posttest was used for pairwise comparisons. Statistically significant (P < .05) results are shown in bold.
kit v2 (Illumina, Inc., San Diego, CA) to prepare individual cDNA libraries. Briefly, this consists of poly-A selection of mRNA and conversion to single-stranded cDNA using random hexamer primer followed by second-strand generation to create double-stranded cDNA. Sequencing adapters were then ligated to the fragmented cDNA. This was followed by polymerase chain reaction amplification and pooling of the libraries. Six cDNA samples were pooled per lane of the flow cell for 100 bp single-end sequencing on a HiSeq 2500 sequencer (Illumina, Inc., San Diego, CA). The raw sequencing data were stored in FASTQ format.
| LCL RNA sequencing data
We downloaded FASTQ files of the gEUVADIS (Genetic European 
| RNA sequence alignment and variant calling
RNA sequence reads from the kidney allograft biopsy specimens and the RNA sequence reads downloaded from gEUVADIS were processed using Genome Reference Consortium human genome reference build 37 (GRCh37) as the reference genome. We used the best practices for RNA sequence variant calling. [27] [28] [29] [30] [31] Briefly, we used Picard (1.107) to sort, add read groups, and remove duplicates in the aligned Binary Alignment/Map (BAM) files as generated by STAR aligner. 32 We then used GATK (version 3. 
| Determination of Het/Hom ratio
We calculated the number of heterozygous variants and the num- 
| Determination of ESTIMATE score
We used the raw sequencing read counts (as generated by STAR aligner in quant mode) as input for the ESTIMATE software, 25 1-Purity score, so that a higher score represents increasing degrees of immune cell infiltration in the biopsy specimens.
| Statistical analysis
We used the nonparametric Kruskal-Wallis test to compare Het/ Hom ratios and ESTIMATE scores among the different diagnostic categories followed by the Dunn's test for pairwise comparisons. We used the Spearman rank-order correlation test for assessing associations. We used Prism 6.07 software (GraphPad Software, La Jolla, CA) for statistical tests and generating graphs. Table 1 Altogether, the data provided in Figure 2 demonstrate that the Banff criteria for biopsy categorization are fulfilled in each instance and that the biopsies included in this study are prototypical for the Banff biopsy classification. 3 Importantly, the biopsies displayed varying degree of intragraft infiltration.
| RE SULTS
| Clinical and biopsy characteristics
| Nucleotide variant calling and Het/Hom ratio computation using the RNA sequencing data from the 1000 genomes project
We leveraged the publically available gEUVADIS RNA sequence data to compute Het/Hom ratios and develop robust estimates of ratios of single genomes representing major races/ethnicities (Table 3) . with Het/Hom ratios obtained using DNA sequencing data. 24 The differences in the Het/Hom ratios among the 5 major populations were statistically significant (P < .0001 Kruskal-Wallis test). By
Dunn's multiple comparison test, differences in the Het/Hom ratios between the YRI population and each of the other 4 populations
were statistically significant (all P < .001) and none of the other pairwise comparisons were significant (P > .05).
| Nucleotide variants calling and Het/Hom ratios computed from the RNA sequencing data of human kidney allograft biopsies
After establishing the range of Het/Hom ratios for single genomes from the 462 LCL included in the 1000 genome project, we next computed Het/Hom ratios for the kidney allograft biopsies representing major diagnostic categories (Table 4 ). Figure 4 shows the Het/Hom ratios, stratified by kidney allograft biopsy diagnosis, and it is evident that the number of heterozygous variants are strikingly higher in the biopsies compared to LCLs and among the biopsies, normal biopsies with minimal or no cellular invasion had the lowest number of heterozygous variants and acute TCMR biopsies with the highest degree of graft infiltration had the highest number of heterozygous variants (Table 3 vs Table 4 ). Accordingly, the Het/Hom ratio was highest for biopsies that were categorized The biopsy infiltration scores and ESTIMATE scores showed a significant association (r s = .77, P < .0001). The ESTIMATE score was positively associated (r s = .54, P < .01) with the sum of graft infiltrating CD3+ cells, CD68+ cells, and CD20+ cells, and among the 2 components contributing to the ESTIMATE score, the immune score was more strongly associated (r s = .55, P < .01) than the stromal score (r s = .37, P = .47) with the sum of graft infiltrating cells. Graft infiltration determined using the ESTIMATE score correlated with Het/ Hom ratio for the 40-kidney allograft biopsies (r = .67, P < .0001, Spearman correlation, Figure 7 ). TA B L E 4 (Continued)
| Het/Hom ratios and biopsy infiltration scores
| Time from transplantation to biopsy and Het/ Hom ratios or the ESTIMATE Scores
We assessed whether time from transplantation to biopsy affects the Het/Hom ratio. Among the 29 biopsies with rejection (acute TCMR, active ABMR, and chronic active ABMR), 9 (31%) biopsies were done within the first 12 months of transplantation. Within each diagnostic category, the correlation between Het/Hom ratio and time from transplantation to biopsy was not statistically significant (P > .05, Spearman correlation, Figure 8) . Similarly, the relation between ESTIMATE score, or the biopsy infiltration score, and time from transplantation to biopsy was not statistically significant (P > .05, Spearman correlation, Figure 8 ).
| D ISCUSS I ON
With the use of RNA sequencing data from 40 unique biopsy samples representing clinically relevant diagnostic categories of human kidney allograft pathology, we tested the hypothesis that the ratio F I G U R E 4 Het/Hom ratio by diagnostic categories of the 40 allograft biopsies. Boxplot and individual data points of the Het/Hom ratios computed from RNA sequencing data of 40 kidney allograft biopsy samples, stratified by kidney allograft biopsy diagnosis category. Acute TCMR, acute T cell-mediated rejection, active ABMR, active antibody-mediated rejection, chronic active ABMR, chronic and active antibody-mediated rejection, IFTA, interstitial fibrosis and tubular atrophy or normal allograft biopsy (normal). Biopsies were categorized using the Banff 2017 update of the Banff '97 classification scheme. The median Het/Hom ratio was 1.149 in acute TCMR, 0.997 in active ABMR, 1.020 in chronic active ABMR, 0.954 in IFTA, and 0.898 in Normal. The difference in Het/Hom ratio among the diagnostic categories was significant (P = .02, Kruskal-Wallis test). By Dunn's test, difference in Het/Hom ratio between acute TCMR and normal (P < .05) was statistically significant. None of the other pairwise comparisons were statistically significant (all P > .05). Het/Hom ratio, heterozygosity to nonreference genome homozygosity ratio of heterozygosity to nonreference genome homozygosity (Het/Hom ratio) can serve as a yardstick of allograft infiltration by recipient's cells. In accord with our postulate, we found that kidney biopsies classified as acute T cell-mediated rejection biopsy had the highest Het/Hom ratio and normal surveillance biopsies with no or minimal infiltration had the lowest Het/Hom ratio, and a positive correlation was demonstrable between the Het/Hom ratio and the biopsy infiltration score.
SNPs have traditionally been identified using DNA sequencing information. Recent advances in computational biology have led to the identification of genomic variants from RNA-Seq data. 20, 21 A priori, there are no reasons that variant calling using RNA-Seq data F I G U R E 6 ESTIMATE score by diagnostic categories of the 40 allograft biopsies. The ESTIMATE score was derived from the RNA sequencing data using the ESTIMATE algorithm. We used the raw sequencing read counts (as generated by STAR aligner in quant mode) as input for the ESTIMATE software, 25 a tool for predicting tumor purity and the presence of infiltrating stromal/immune cells in tumor tissues using gene expression data. The ESTIMATE algorithm combines gene expression of 141 stromal and 141 immune genes and performs singlesample gene set-enrichment analysis for each set of selected genes, calculates a stromal score and an immune score to predict the level of infiltrating stromal and immune cells, respectively, and combines these individual scores to provide a final score called the ESTIMATE score, which is converted to a tumor purity score, ranging from 0 to 1, with 1 denoting a highly pure sample. For simplicity, we represent ESTIMATE score as 1-Purity score, so that a higher score represents increasing degrees of immune cell infiltration in the biopsy specimens. In the y-axis, the 1-Purity score ranges from 0 to 1, where 0 denotes a highly pure sample. Biopsies were categorized using the Banff 2017 update of the Banff '97 classification. The median 1-Purity score was 0.394 in acute TCMR, 0.307 in active ABMR, 0.278 in chronic active ABMR, 0.170 in IFTA, and 0.098 in normal. The difference in the 1-Purity score among the groups was statistically significant (P < .001, Kruskal-Wallis test). By Dunn's test, difference in ESTIMATE score between acute TCMR and IFTA (P < .01), and between acute TCMR and normal (P < .001) was statistically significant. None of the other pairwise comparisons were statistically significant (all P > .05). ABMR, antibody-mediated rejection; ESTIMATE, estimation of stromal and immune cells in malignant tumors using expression data; Het/Hom ratio, heterozygosity to nonreference genome homozygosity ratio; IFTA, interstitial fibrosis and tubular atrophy; TCMR, T cell-mediated rejection F I G U R E 7 Association between Het/Hom ratio and ESTIMATE score of the 40 allograft biopsies. The Het/Hom ratio and the ESTIMATE score were derived from the RNA sequencing data. We show the ESTIMATE score as a 1-Purity score. The association between Het/ Hom ratio and 1-Purity score was statistically significant (r = .67, P < .0001, Spearman rank-order correlation). ABMR, antibody-mediated rejection; ESTIMATE, estimation of stromal and immune cells in malignant tumors using expression data; Het/Hom ratio, heterozygosity to nonreference genome homozygosity ratio; IFTA, interstitial fibrosis and tubular atrophy; TCMR, T cell-mediated rejection should be more accurate compared to variant calling using DNA sequence data. However, RNA-Seq data have the additional advantage of characterizing gene expression patterns.
1-Purity (ESTIMATE) Score
The ESTIMATE score has hitherto been used to reflect tumor purity and is based on the expression of 141 selected stromal signature genes and of 141 selected immune signature genes. In accord with the notion that graft "contamination" by varying degrees of infiltrating cells would impact the ESTIMATE score, it was highest for acute rejection biopsies, lowest for normal allograft biopsies, and differed significantly among biopsy diagnoses characterized by different degrees of graft infiltration. Deconvolution of bulk RNA sequencing data can yield information regarding cell composition of complex tissues based on their gene expression patterns. The ESTIMATE score computed in this study is a composite score of immune and stromal signature scores. We demonstrate that the ESTIMATE score is positively associated with the sum of graft infiltrating CD3+ cells, CD68+ cells, and CD20+ cells, and that between the 2 components contributing to the ESTIMATE score, the immune score is more strongly associated than the stromal score with the sum of graft infiltrating cells. Further deconvolution (ie, identification of cell subtypes such as T cell subsets) is not feasible using the ESTIMATE score and requires a priori availability of reference gene expression profiles 34 and statistical workflows such as DeconRNASeq 35 to deconvolve the bulk RNA sequencing data generated in our study.
As anticipated, the biopsy Het/Hom ratios and the ESTIMATE scores were highly correlated. Taken together, these observations confirm our hypothesis that the total burden of cellular invasion of the allograft during allograft rejection can be interrogated using the ratio between genetic material derived from the donor cells and the Our study is significant from both biologic and clinical perspectives. Not only the execution phase but also the priming phase of allograft rejection is likely to be dependent upon the physical contact between the recipient's immune cells and graft parenchymal cells and in all probabilities assessment using mRNA is likely to be more sensitive than using proteins or cells as parameters of graft infiltration. From a clinical perspective, the concerns related to variations in the interpretation of biopsy findings, less than optimal reproducibility for grading severity of histological lesions, and poor sensitivity for detecting tubulitis using conventional microscopy are all mitigated using RNA sequencing data.
Our study has several limitations. Although the kidney allograft biopsies included in this study were selected to represent most of the major types of graft pathology, our biopsy sample size F I G U R E 8 Lack of association between the time from transplantation to biopsy and Het/Hom ratio, ESTIMATE score, or the biopsy infiltration score. Scatterplot depicts the relationship between the time from transplantation to biopsy and Het/Hom ratio (A), ESTIMATE score (1-Purity) (B), and biopsy infiltration score (C) for all 40 biopsies. Within each diagnostic category, there was no significant correlation between the time from transplantation to biopsy and Het/Hom ratio, ESTIMATE score, or the biopsy infiltration score (P > .5, Spearman rank-order correlation). ABMR, antibody-mediated rejection; ESTIMATE, estimation of stromal and immune cells in malignant tumors using expression data; Het/ Hom ratio, heterozygosity to nonreference genome homozygosity ratio; IFTA, interstitial fibrosis and tubular atrophy; TCMR, T cellmediated rejection 
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